Vertical: CNMBase Year: 2025
Market Size (2025)
$176.39M
Projected (2032)
$337.77M
CAGR (2022–2032)
9.8%
Key Players
9+
Market Overview
The global Bacillus pumilus market was valued at USD 176.39 million in 2025 and is projected to reach USD 337.77 million by 2032, registering a CAGR of 9.71% during the forecast period 2026–2032. The market has expanded from USD 132.99 million in 2022, and is expected to add USD 161.39 million in absolute value between 2025 and 2032.
Bacillus pumilus is an aerobic, Gram-positive, endospore-forming bacterium that is commercialised in agriculture primarily as a microbial biofungicide and plant health agent. Commercial strains such as QST 2808 (marketed as Sonata) and GB34 (marketed as Yield Shield) have been registered by the US Environmental Protection Agency for close to two decades, and a growing number of multi-strain Bacillus formulations containing B. pumilus have been registered in Brazil and other Latin American markets since 2021. Demand is supported by the need to manage fungal diseases with tools that leave no regulated residues, by the role of biological modes of action in fungicide resistance management, and by government programmes that promote biological inputs in major agricultural economies.
Key Findings
By formulation, Wettable Powder is the largest segment, valued at USD 79.37 million in 2025 (45.0% share), while Liquid is the fastest-growing segment, with a CAGR of 10.97% during 2026–2032.
By crop type, Fruits & Vegetables is both the largest segment, with a 2025 value of USD 88.19 million (50.0% share), and the fastest-growing segment, with a CAGR of 10.36% during 2026–2032.
By application method, Soil Treatment is the largest segment, valued at USD 79.37 million in 2025 (45.0% share), while Seed Treatment is the fastest-growing segment, with a CAGR of 11.28% during 2026–2032.
North America is the leading region, valued at USD 58.21 million in 2025 (33.0% of the global market), while Asia Pacific is the fastest-growing region, with a CAGR of 11.87% during 2026–2032.
The U.S. is the leading country, valued at USD 47.73 million in 2025 (27.1% of the global market), while India is the fastest-growing country, with a CAGR of 13.78% during 2026–2032.
Segmentation Summary
Formulation: Wettable powder formulations account for the largest share (45.0% in 2025), reflecting the suitability of spore-forming Bacillus strains to drying processes and the long ambient shelf life of powder products. Liquid formulations (35.0% share) are expanding fastest at a CAGR of 10.97%, as suspension concentrates gain preference for tank-mix compatibility, seed-treatment slurries and fertigation. Granules account for 20.0% of the 2025 market and grow at a CAGR of 10.14%.
Crop Type: Fruits & vegetables represent 50.0% of 2025 demand and also grow fastest at a CAGR of 10.36%, supported by residue-sensitive export horticulture and high disease pressure from mildews and Botrytis. Cereals & grains (25.0% share) grow at 8.09%, while the Others category, which includes oilseeds such as soybean, sugarcane and other field and specialty crops, holds 25.0% and grows at 9.93%.
Application Method: Soil treatment is the largest application method (45.0% share in 2025), driven by the use of B. pumilus against soil-borne pathogens and in root-zone colonisation programmes. Seed treatment is the fastest-growing method at a CAGR of 11.28%, as seed companies and growers adopt biological seed-applied packages. Foliar application accounts for 25.0% of the market and grows at a CAGR of 9.04%.
Competitive Landscape Summary
The market is moderately fragmented. Bayer holds the most established position through its QST 2808-based Sonata (including the former Ballad Plus brand) and GB34-based Yield Shield products. In Latin America, a group of companies markets multi-strain Bacillus biofungicides that contain the B. pumilus strain CNPSo 3203, including BioFirst Group's Biotrop (Bombardeiro/Lastro and Bioshield), Koppert (Caravan/Grabber) and Syngenta (Reverb), while ADAMA distributes a comparable product (Atena) in Peru. Premier Tech supplies B. pumilus strain PTB180 in biofungicide and growing-media products, and Brazilian specialists such as Gênica, Solubio and Apoena Biosoluções hold registered B. pumilus-containing products. Competition is shaped by strain ownership, registration portfolios, formulation quality and access to distribution, and the period since 2022 has been marked by acquisitions, equity investments and licensing agreements in agricultural biologicals.
Challenges and Opportunities
The principal challenges are regulatory. In the European Union, the approval of Bacillus pumilus QST 2808 under Regulation (EC) No 1107/2009 expired on 31 August 2024 after no renewal application was submitted, and microbial biostimulants under the EU Fertilising Products Regulation are currently limited to four groups of micro-organisms that do not include Bacillus. In India, B. pumilus does not feature among the bio-fungicides listed by the Central Insecticides Board and Registration Committee as on 31 March 2024. Variable field efficacy relative to synthetic fungicides and the need for grower education also restrain adoption.
Opportunities are concentrated in seed treatment, in multi-strain consortia that combine B. pumilus with other Bacillus species, in the rapid expansion of biological inputs in Brazil following the Bioinputs Law (Law No. 15,070 of December 2024), and in Asia Pacific, which is the fastest-growing region. Controlled-environment agriculture and growing-media incorporation provide further avenues for growth.
Future Outlook
The market is projected to nearly double between 2025 and 2032, from USD 176.39 million to USD 337.77 million. Growth will be led by liquid formulations, seed treatment and fruits & vegetables, while Asia Pacific and the Middle East & Africa will gain share from a smaller base. North America is expected to remain the largest regional market through 2032. The pace of regulatory approvals for microbial active substances, the commercial strategies of large crop protection companies in biologicals, and continued investment in fermentation and formulation capacity will be the main determinants of the market trajectory.
The Bacillus Pumilus Market market is projected to grow at a CAGR of 9.8% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Bacillus pumilus is an aerobic, Gram-positive, rod-shaped bacterium that forms highly resistant endospores. Selected strains are used as the active ingredient of microbial plant protection and plant health products. Their activity is based on several mechanisms, including colonisation of leaf, seed and root surfaces, competition with pathogens for space and nutrients, production of antifungal metabolites that inhibit spore germination and mycelial growth, and induction of systemic resistance in the host plant. Certain strains also show plant-growth-promoting traits. The capacity to form endospores allows the organism to be produced by industrial fermentation and formulated into stable commercial products.
For the purpose of this study, the Bacillus pumilus market comprises the value of formulated commercial products that contain one or more Bacillus pumilus strains as an active ingredient and are used in crop production, whether as single-strain products or as multi-strain consortia combined with other micro-organisms. The market includes products supplied as wettable powders, liquids and granules and applied by soil treatment, seed treatment or foliar application across fruits & vegetables, cereals & grains and other crops.
The study excludes B. pumilus used in animal feed and probiotics, human health products, industrial enzymes, bioremediation and wastewater treatment; products based on other Bacillus species that do not contain B. pumilus; and microbial cultures produced on-farm for own use that are not sold as commercial products.
Scope of the Study
The study provides historic market data for 2022–2024, base-year estimates for 2025 and forecasts for 2026–2032. All market values are presented in USD Million, and growth rates are presented as the compound annual growth rate (CAGR) for 2026–2032.
Research Objectives
To estimate the size of the global Bacillus pumilus market for 2022–2025 and forecast it for 2026–2032 in USD Million.
To analyse the market by formulation (wettable powder, liquid and granules) and identify the formats gaining share.
To assess demand across fruits & vegetables, cereals & grains and other crops, and the disease-management needs driving use in each.
To evaluate the adoption of soil, seed and foliar application methods for B. pumilus-based products.
To quantify the market across five regions and 19 country-level markets and identify the fastest-growing geographies.
To examine the drivers, restraints, opportunities and trends shaping the market, including the regulatory status of B. pumilus strains in key jurisdictions.
To profile the competitive environment, including the positioning of leading suppliers and key developments since 2022.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study followed a structured research process combining secondary research, primary research and analytical modelling. The process began with a definition of the market scope and segmentation, followed by the collection of information on registered B. pumilus products, their producers, crops and application methods. Market size was estimated for the base year using top-down and bottom-up approaches, validated through triangulation and primary interactions, and projected over the forecast period using a factor-based model. All estimates were reviewed for internal consistency across segments, regions and countries.
Secondary Research
Secondary research was used to build an understanding of the product, its regulatory status, its supply base and the demand environment. Sources relevant to this industry included:
Regulatory and government bodies: pesticide and biopesticide registers and decisions of the US Environmental Protection Agency, the European Commission and the European Food Safety Authority, India's Central Insecticides Board and Registration Committee, Brazil's Ministry of Agriculture and Livestock (MAPA), China's Institute for the Control of Agrochemicals (ICAMA) and Health Canada's Pest Management Regulatory Agency.
Agricultural statistics: crop area, production and trade data from national agriculture ministries and the Food and Agriculture Organization of the United Nations.
Industry associations: biological crop protection and biostimulant associations at national, regional and international level.
Company sources: annual reports, financial results, investor presentations, product labels, technical data sheets and press releases of manufacturers and distributors.
Trade and scientific literature: agricultural trade journals, peer-reviewed research on Bacillus strains and their efficacy, and conference proceedings.
Paid databases: company, product registration and trade databases used for cross-checking.
Primary Research
Primary research was conducted to validate secondary findings, fill information gaps and test the assumptions used in the market model. Interviews were held with participants on both the supply and demand sides of the market.
Supply side: executives and product managers of biological crop protection manufacturers, fermentation and formulation specialists, regulatory affairs professionals and distributors of crop inputs.
Demand side: growers of fruits, vegetables and field crops, agronomists and crop advisors, seed companies and seed treatment service providers, and greenhouse and nursery operators.
Objectives: to validate product pricing and volumes, understand adoption patterns by crop and application method, assess regional demand conditions, and obtain views on regulatory and competitive developments.
Market Size Estimation
Top-down approach: The broader agricultural biologicals and microbial biofungicide markets were used as the starting point. The share attributable to Bacillus-based products, and within that to products containing B. pumilus, was derived using product registration counts, company revenue information and expert inputs, and allocated across regions and segments.
Bottom-up approach: Country-level demand was built from the treated crop area, adoption rates of biological fungicides, application rates and average product prices by formulation and application method. Country values were aggregated to regional and global totals.
Data triangulation: The results of the two approaches were compared and reconciled, and the final estimates were validated through primary interviews. Segment values were checked to ensure that they sum to the corresponding regional and global totals.
Forecasting Methodology
The forecast was developed using a factor-based model applied to the base-year estimates. Factors considered include crop area and output trends, the adoption of integrated pest management and organic practices, regulatory developments affecting microbial active substances, residue standards in export markets, changes in disease pressure, pricing trends, new product registrations and the investment plans of market participants. Each factor was assessed for its expected impact over 2026–2027, 2028–2030 and 2031–2032, and growth rates were applied at the country and segment level before aggregation.
Assumptions and Limitations
Market values are expressed in nominal USD at constant exchange rates, and the effect of currency fluctuations is not modelled.
Values represent the market for formulated products at manufacturer selling prices.
Multi-strain products containing B. pumilus are included in the market, with value attributed to the B. pumilus market as defined in the study scope.
The forecast assumes no major disruption to agricultural production or trade and a broadly stable regulatory framework for microbial products, except for changes already enacted.
Information on privately held companies and on informal distribution channels is limited, which may affect the precision of estimates for some countries.
Rest-of-region categories aggregate countries for which individual estimates are not presented.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The global Bacillus pumilus market is moderately fragmented. A small number of strains account for most commercial activity: QST 2808 and GB34, held by Bayer, have the longest commercial history in North America, while strain CNPSo 3203 is formulated in Brazil by Biotrop and marketed in multi-strain or single-strain products by several companies. Alongside these, companies such as Premier Tech, Gênica, Solubio and Apoena Biosoluções market products based on their own strains.
Competition takes place along several dimensions: ownership of proprietary strains and registrations, breadth of crop and disease label claims, formulation quality and shelf life, field-trial evidence, and access to distribution. Large crop protection companies compete through global distribution networks and partnerships with biological specialists, while regional producers compete on price, local technical support and speed of registration. The period since 2022 has been marked by acquisitions, equity investments and licensing agreements, and further consolidation is expected as major companies expand their biological portfolios.
Key Player Positioning
Leaders: Bayer is the leading supplier, based on its established QST 2808 (Sonata) and GB34 (Yield Shield) products, its registrations in the United States, Brazil and other markets, and its global crop protection distribution network. Bayer's Crop Science division reported sales of EUR 21.6 billion in fiscal 2025.
Challengers: Syngenta, BioFirst Group (through Biotrop) and Koppert hold strong positions in Latin America through B. pumilus-containing biofungicides registered in Brazil. Syngenta Group reported sales of USD 28.4 billion in 2025 and has set out an ambition to become the global leader in biologicals. Biotrop, which reported revenue of approximately BRL 900 million in 2025, provides formulation capacity for several products in the region, and Koppert combines a global biological crop protection footprint with a large Brazilian business.
Niche players: Premier Tech focuses on greenhouse and nursery growers through biofungicide and growing-media products containing B. pumilus PTB180. Gênica, Solubio and Apoena Biosoluções are Brazilian specialists with registered B. pumilus-containing products targeting sugarcane, grains and horticulture. ADAMA participates as a distributor of a B. pumilus-containing biofungicide in Peru.
Competitor Dashboard
The competitor dashboard rates each profiled company on four parameters relevant to its position in the Bacillus pumilus market: breadth of product portfolio, regional presence, strategic alliances, and industry experience.
Threat of New Entrants: Medium
Fermentation technology for Bacillus species is well understood, and production capital requirements are moderate, particularly in emerging markets.
Registration requirements, strain characterisation and efficacy data create time and cost barriers to entry in regulated markets.
Established relationships between leading suppliers and distributors limit access to key channels.
Bargaining Power of Suppliers: Low
Fermentation media, carriers and packaging materials are widely available commodities with multiple sources.
Strain ownership is generally held by the manufacturers themselves, reducing dependence on external technology suppliers.
Contract fermentation capacity is available, although specialised formulation capability is more concentrated.
Bargaining Power of Buyers: Medium
Individual growers are fragmented, but large distributors, cooperatives and seed companies negotiate significant volumes.
Buyers can choose among many biological and chemical alternatives, which constrains pricing.
Technical support and proven field performance increase customer loyalty for established brands.
Threat of Substitutes: High
Products based on Bacillus subtilis, B. amyloliquefaciens, B. velezensis, Trichoderma and other micro-organisms target similar diseases.
Synthetic fungicides remain widely available, cost-effective and familiar to growers.
Cultural practices and resistant crop varieties also reduce the need for disease-control products.
Intensity of Competitive Rivalry: High
The market includes global crop protection companies, specialist biological firms and many regional producers.
Rapid growth of biologicals in Brazil has attracted numerous competitors with multi-strain Bacillus products.
Competition increasingly focuses on formulation quality, label claims, technical service and distribution partnerships.
Threat of New Entrants: Medium; Moderate capital needs offset by registration barriers.
Bargaining Power of Suppliers: Low; Commodity inputs; strains held by manufacturers.
Bargaining Power of Buyers: Medium; Large distributors and many alternatives.
Threat of Substitutes: High; Other microbial species and synthetic fungicides.
Intensity of Competitive Rivalry: High; Many global, specialist and regional suppliers.
Market estimates by geography (2032)
InsightNorth America leads with $104.61M by 2032, while Asia Pacific is projected to grow fastest at a 11.9% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $44.70M | $68.94M | $104.61M | 8.9% | 31% |
| Europe | $32.66M | $50.10M | $75.86M | 8.8% | 22% |
| Asia Pacific | $22.65M | $39.90M | $69.78M | 11.9% | 21% |
| Latin America | $27.66M | $45.00M | $72.82M | 10.2% | 22% |
| Middle East & Africa | $5.32M | $8.72M | $14.69M | 10.7% | 4% |
| Total | $132.99M | $212.66M | $337.77M | 9.8% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$337.77M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Wettable Powder | $140.18M | 8.6% | 42% |
| Liquid | $128.15M | 11.0% | 38% |
| Granules | $69.45M | 10.2% | 21% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Bacillus Pumilus Market covering market dynamics, competitive landscape, and strategic outlook.
The Bacillus Pumilus Market market is projected to reach $337.77M by 2032, growing at 9.8% CAGR. The Wettable Powder segment holds the largest share.
The Bacillus pumilus market is shaped by the interaction of agricultural demand, disease pressure, regulation of chemical and biological crop protection, and the commercial strategies of input suppliers. This chapter assesses the macro and micro factors influencing the market, followed by a discussion of the key drivers, restraints, opportunities, trends and challenges. The impact scores presented in the growth factor analysis are analyst assessments on a scale of 1 to 10, where a higher score indicates a stronger impact on the market in the specified period.
Demand for Residue-Free Produce and Tightening Residue Standards
Retailers, importers and regulators are applying increasingly strict limits on pesticide residues in fresh produce, which pushes growers towards crop protection tools that do not leave regulated residues close to harvest. B. pumilus products are well suited to this need. In the United States, Bacillus pumilus strain QST 2808 is exempt from the requirement of a tolerance on all agricultural commodities when used in accordance with label directions (40 CFR 180.1255), and strain GB34 holds a tolerance exemption for seed-treatment use (40 CFR 180.1224). In the European Union, the European Food Safety Authority concluded in its 2020 review that maximum residue levels for QST 2808 were not necessary, and the substance was placed in Annex IV of Regulation (EC) No 396/2005. Exporters of grapes, berries, avocados and vegetables in Latin America, Africa and Asia must meet the residue requirements of destination markets, and late-season biological applications allow them to protect crops while managing residue profiles. This dynamic supports the fruits & vegetables segment, which accounts for half of global demand.
Fungicide Resistance Management and Integrated Pest Management
Repeated use of single-site synthetic fungicides has led to resistance in pathogens such as powdery mildews, Botrytis and soybean rust, reducing the effectiveness of established chemistries. Biological fungicides with multiple modes of action are increasingly used in rotation or tank mixes to delay resistance and extend the life of chemical products. In Brazil, multi-strain Bacillus biofungicides containing B. pumilus are positioned as multi-site products for late-season soybean diseases, and products such as Caravan are labelled against diseases including Septoria, Cercospora, Corynespora and rusts. Integrated pest management programmes promoted by extension services, food companies and certification schemes formally incorporate biological products, and the USDA National Organic Program permits biological substances for disease control where cultural practices are insufficient. These practices create recurring demand for B. pumilus products across speciality and row crops.
Policy Support for Biological Inputs
Governments in key agricultural economies have introduced policies that facilitate the registration and use of biological inputs. Brazil established its National Bioinputs Program through Decree No. 10,375 of May 2020 and enacted Law No. 15,070 in December 2024, which creates a dedicated legal framework for the production, registration, marketing and use of bioinputs. In the United States, the EPA's Biopesticides and Pollution Prevention Division handles biopesticide registrations, which generally require less data than conventional pesticides. China operates a priority review channel for microbial pesticides, and India brought biostimulants under the Fertiliser (Inorganic, Organic or Mixed) (Control) Order in 2021 and simplified the procedure in 2024. In Japan, the MIDORI Strategy for Sustainable Food Systems sets long-term targets to reduce the risk-weighted use of chemical pesticides and expand organic farming. Such measures lower barriers to market entry and encourage growers to trial biological products.
Investment and Consolidation in Agricultural Biologicals
Large crop protection companies and specialist biological firms are investing heavily in the biologicals segment, which increases the commercial reach of B. pumilus products. Biobest (now BioFirst Group) completed the acquisition of approximately 85% of Brazil's Biotrop in December 2023 at an enterprise value of BRL 2.8 billion. Koppert received a EUR 140 million investment from HAL Investments in February 2024 to expand production capacity. Syngenta announced in June 2025 its ambition to become the global leader in biologicals, with a biostimulant plant in Orangeburg, South Carolina, with capacity of 16,000 tonnes per year, and Bayer has set a target of more than EUR 1.5 billion in biologicals sales by 2035. These investments expand fermentation capacity, strengthen distribution and fund field development, which supports adoption of B. pumilus-based products in new crops and geographies.
Growth of Biological Seed Treatment
Seed treatment is the fastest-growing application method, with a CAGR of 11.28% during 2026–2032. Seed-applied biologicals require small quantities of product per hectare, can be applied by seed companies in controlled conditions, and protect seedlings against soil-borne pathogens during establishment. The B. pumilus strain GB34 is registered in the United States for seed treatment, and seed companies increasingly bundle biological components into their treatment packages for soybean, corn, wheat and vegetables. Suppliers that develop seed-compatible strains and formulations with long on-seed survival are well placed to capture this opportunity.
Multi-Strain Consortia and Combination Products
Products that combine B. pumilus with other Bacillus species provide a broader spectrum of activity and multiple modes of action. In Brazil, products such as Bombardeiro/Lastro, Bioshield, Reverb and Atena combine B. pumilus CNPSo 3203 with B. subtilis and B. velezensis strains, and Gênica's agBest combines five Bacillus strains, including B. pumilus, against Fusarium and root-lesion nematodes. Combinations with biostimulant ingredients, nutrients and conventional fungicides offer further possibilities for differentiated products and premium pricing.
Expansion in Emerging Agricultural Markets
Asia Pacific is the fastest-growing region, with a CAGR of 11.87% during 2026–2032, followed by the Middle East & Africa and Latin America. Large areas of horticultural and field crops in China, India and Southeast Asia, government programmes promoting natural and organic farming, and growing export horticulture in Latin America and Africa create substantial opportunities. Brazil's Bioinputs Law is expected to provide greater legal certainty for registration and commercialisation, while controlled-environment agriculture in the Gulf states creates demand for biological products suited to greenhouse and hydroponic production.
Regulatory Complexity and Uneven Approval Status
Microbial active substances must be approved separately in each jurisdiction, and the regulatory status of B. pumilus differs significantly across markets. In the European Union, the approval of Bacillus pumilus QST 2808 expired on 31 August 2024 after Commission Implementing Regulation (EU) 2023/1447 withdrew the extension of its approval period because no renewal application had been submitted. Under the EU Fertilising Products Regulation (EU) 2019/1009, the component material category for microbial biostimulants currently covers only Azotobacter, Azospirillum, Rhizobium and mycorrhizal fungi. In India, B. pumilus is not among the bio-fungicides listed by the Central Insecticides Board and Registration Committee as on 31 March 2024. These differences restrict the ability of suppliers to commercialise products globally and increase the cost of market entry.
Variable Field Performance and Grower Perception
The efficacy of microbial products depends on environmental conditions, application timing, population establishment and compatibility with other inputs. B. pumilus products are generally preventive and act more slowly than many synthetic fungicides, and their performance under high disease pressure can be inconsistent. Growers accustomed to chemical fungicides may perceive biologicals as less reliable, particularly in broad-acre crops where margins are thin. Building confidence requires field demonstrations, technical support and evidence from independent trials, which lengthens the adoption cycle.
Product Quality, Shelf Life and Informal Supply
Product quality depends on maintaining viable spore counts throughout storage and distribution. Inconsistent quality, inadequate labelling and the presence of unregistered or substandard products in informal channels can undermine grower trust in biological inputs. In India, provisional registrations for biostimulants were not extended beyond June 2025, and industry reports indicate that more than 9,000 provisional product registrations were cancelled, illustrating the scale of quality and compliance issues in some emerging markets.
Shift Towards Liquid and Suspension Concentrate Formulations
Liquid formulations are the fastest-growing formulation segment, with a CAGR of 10.97% during 2026–2032. Most of the B. pumilus products registered in Brazil since 2021 are suspension concentrates, and Sonata in the United States is a liquid product diluted in water before application. Liquid formats offer convenient measurement, compatibility with spray programmes and seed-treatment equipment, and lower dust exposure for operators.
Partnerships Between Agrochemical Majors and Biological Specialists
Large crop protection companies increasingly access biological technologies through licensing, distribution and development partnerships rather than in-house discovery alone. Examples include Bayer's partnerships with Kimitec, AlphaBio Control, M2i and Ginkgo Bioworks; Syngenta's collaborations with Biotrop and Amoéba; and ADAMA's distribution of a B. pumilus-containing biofungicide in Peru. Such arrangements give specialist producers access to global distribution and give major companies a broader biological portfolio.
Incorporation of Biologicals into Growing Media and Controlled-Environment Agriculture
Greenhouse, nursery and vertical-farming operators favour biological products that can be incorporated into the growing substrate. Premier Tech's PRO-MIX growing media containing B. pumilus strain PTB180, registered by the US EPA, illustrate this trend. The approach provides root-zone protection from the start of the crop cycle and reduces labour for separate applications.
Rising Data Requirements and Regulatory Adaptation
Regulators are updating the frameworks for microbial products. The European Union adopted Regulations (EU) 2022/1438, 2022/1439, 2022/1440 and 2022/1441, applying from 21 November 2022, which set out specific approval criteria and data requirements for micro-organisms. While these rules are designed to reflect the biology of micro-organisms more accurately, suppliers must still invest in dossiers, strain characterisation and efficacy data, which remains a challenge for smaller companies seeking approvals in multiple jurisdictions.
The value chain of the Bacillus pumilus market extends from strain discovery and fermentation inputs to manufacturing, distribution and use by growers. Value addition is concentrated in strain development and registration, fermentation and formulation know-how, and technical selling.
North America
United States: Microbial pesticides are registered by the Environmental Protection Agency under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), with tolerances or exemptions established under the Federal Food, Drug, and Cosmetic Act. EPA's list of biopesticide active ingredients includes B. pumilus strains GB34, QST 2808 and BU F-33.
Tolerance exemptions apply to B. pumilus QST 2808 on all agricultural commodities (40 CFR 180.1255) and to B. pumilus GB34 for seed-treatment use (40 CFR 180.1224). B. pumilus is subject to periodic registration review by EPA.
Organic production: The USDA National Organic Program (7 CFR Part 205) allows biological substances for disease control where cultural practices are insufficient.
Canada: Pest control products, including microbial products, are regulated by Health Canada's Pest Management Regulatory Agency under the Pest Control Products Act.
Europe
Plant protection products are regulated under Regulation (EC) No 1107/2009. Bacillus pumilus QST 2808 was approved by Commission Implementing Regulation (EU) No 485/2014 for the period 1 September 2014 to 31 August 2024; Implementing Regulation (EU) 2023/1447 withdrew the extension of this period, and the approval expired on 31 August 2024.
Regulations (EU) 2022/1438, 2022/1439, 2022/1440 and 2022/1441, applicable from 21 November 2022, introduced specific approval criteria and data requirements for micro-organisms.
Regulation (EU) 2019/1009 on fertilising products, fully applicable since 16 July 2022, provides for CE-marked microbial biostimulants, although the eligible micro-organisms are currently limited to Azotobacter, Azospirillum, Rhizobium and mycorrhizal fungi.
The European Commission's proposed Sustainable Use Regulation, which included a 50% reduction target for chemical pesticide use and risk by 2030, was withdrawn in 2024.
Asia Pacific
India: Biopesticides are registered by the Central Insecticides Board and Registration Committee under the Insecticides Act, 1968. Biostimulants have been regulated under the Fertiliser (Control) Order since 2021, with revised procedures notified in May 2024.
China: Pesticide registration, including microbial pesticides, is administered by the Institute for the Control of Agrochemicals (ICAMA) under the Ministry of Agriculture and Rural Affairs, with a priority review channel for microbial products.
Japan: Agricultural chemicals are regulated under the Agricultural Chemicals Regulation Act, and the MIDORI Strategy for Sustainable Food Systems promotes reduced chemical pesticide risk.
Australia: Agricultural chemical products, including biologicals, are registered by the Australian Pesticides and Veterinary Medicines Authority.
Latin America
Brazil: Law No. 14,785 of 27 December 2023 replaced the previous pesticides law and sets statutory review timelines. Law No. 15,070 of 23 December 2024 established a dedicated framework for bioinputs, including mandatory registration of commercial bioinputs and provisions for on-farm production for own use. The National Bioinputs Program was created by Decree No. 10,375 of 2020.
Argentina: Plant protection products are registered by the National Agri-Food Health and Quality Service (SENASA).
Peru: Biological plant protection products are registered with the National Agrarian Health Service (SENASA).
Middle East & Africa
South Africa: Agricultural remedies are registered under the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act No. 36 of 1947).
Gulf Cooperation Council countries register pesticides through national authorities, and food security strategies in Saudi Arabia and the UAE support controlled-environment and sustainable agriculture.
International guidance: The FAO/WHO Guidelines for the registration of microbial, botanical and semiochemical pest control agents (2017) provide a reference framework for countries developing microbial registration systems.
Aug 2022: ADAMA; Product Launch; Launched Protege, a microbial fungicide and nematicide based on three Bacillus species, for soybean and sugarcane in Brazil.
Feb 2023: Bayer; Partnership; Entered a strategic partnership with Kimitec to develop and commercialise biocontrol products and biostimulants derived from natural molecules.
Aug 2023: Premier Tech; Registration; Received US EPA registration for PRO-MIX CX BIOFUNGICIDE, a growing medium containing B. pumilus strain PTB180.
Dec 2023: BioFirst Group (Biobest); Acquisition; Completed the acquisition of approximately 85% of Brazil-based Biotrop at an enterprise value of BRL 2.8 billion.
Feb 2024: Koppert; Investment; Received a EUR 140 million investment from HAL Investments to expand production capacity and support growth.
Apr 2024: BioFirst Group; Expansion; Renamed from Biobest Group to BioFirst Group and inaugurated a EUR 12 million production facility in Westerlo, Belgium.
Apr 2024: Solubio; Investment; Aqua Capital took control of Solubio through a capital injection of approximately BRL 100 million.
Apr 2024: Bayer; Licensing; Obtained an exclusive licence from AlphaBio Control for a bioinsecticide for arable crops, with launch targeted for 2028.
May 2024: Premier Tech; Registration; US EPA accepted an amended label for GHA 180 Biological Fungicide based on B. pumilus strain PTB180.
Jun 2024: Gênica; Investment; Raised BRL 68 million in a Series C funding round led by Mitsubishi Corporation.
Jul 2024: Premier Tech; Rebranding; Unified its biological products under the AGTIV brand; PRO-MIX BIOFUNGICIDE became AGTIV DEFEND.
Dec 2024: Syngenta; Acquisition; Acquired Intrinsyx Bio, a US developer of nutrient-use-efficiency biologicals.
Apr 2025: BioFirst Group; Acquisition; Became the sole shareholder of Bugs for Bugs (Australia) by acquiring the remaining 50.01% stake.
Jun 2025: Syngenta; Expansion; Announced its ambition to lead the global biologicals market; its Orangeburg, South Carolina, plant with 16,000 tonnes of annual capacity is operational.
Jul 2025: Bayer; Partnership; Expanded its distribution partnership with M2i Group for pheromone-based biological crop protection to Asia Pacific, Latin America and the US.
Oct 2025: Bayer; Partnership; Extended its multi-year agricultural biologicals partnership with Ginkgo Bioworks.
Jan 2026: BioFirst Group (Biotrop); Expansion; Biotrop assumed management of BioWorks, extending its biopesticide operations to the US, Europe and Africa.
Sep 2026: Syngenta; Partnership; Signed an exclusive distribution agreement with Amoéba for the AXP20 biofungicide for cereals in Europe.
Political
Government programmes such as Brazil's National Bioinputs Program, India's natural farming initiatives and Japan's MIDORI Strategy promote biological inputs.
Changes in policy direction, such as the withdrawal of the EU Sustainable Use Regulation proposal, can slow the substitution of chemical pesticides.
Trade policy and import regulations affect the cross-border movement of microbial products.
Economic
Farm incomes and commodity prices influence grower spending on crop protection inputs.
Higher value per hectare in fruits and vegetables supports adoption of premium biological products.
Investment flows into agricultural biologicals, including acquisitions and venture funding, expand production and distribution capacity.
Social
Consumer preference for residue-free and organically produced food increases retailer demand for biological crop protection.
Concerns about operator safety and environmental impact of pesticides influence grower choices.
Awareness and technical knowledge of biologicals among smallholder farmers remains limited in many emerging markets.
Technological
Advances in strain screening, genomics and fermentation improve product potency and production efficiency.
Improved formulations extend shelf life and enable compatibility with seed treatments and chemical tank mixes.
Digital agronomy tools support targeted, preventive application of biological products.
Environmental
Climate change is altering the distribution and intensity of fungal diseases, increasing demand for disease management.
Biological products support soil health and biodiversity objectives within sustainable agriculture programmes.
Environmental conditions such as temperature, humidity and UV exposure affect the field performance of microbial products.
Legal
Registration requirements for microbial active substances differ by jurisdiction and determine market access.
Tolerance exemptions and MRL rules for B. pumilus in the United States and the European Union facilitate use close to harvest.
Intellectual property protection for proprietary strains and data protection periods for registrations shape competition.
Profiles of 106 companies operating in the Bacillus Pumilus Market market, including revenue, employee count, and market positioning where available.
Showing 106 of 106 companies
Bayer is a German life-science group with three businesses: Crop Science, Pharmaceuticals and Consumer Health. It is the world's largest combined seed, trait and crop-protection supplier, a mid-sized prescription-drug maker, and a top-five self-care company. Fiscal 2025 sales were EUR 45.6 billion. The 2018 purchase of Monsanto brought leading corn and soybean genetics but also glyphosate and PCB litigation, which has consumed well over EUR 10 billion in settlements and produced net losses in 2023, 2024 and 2025. Under CEO Bill Anderson the company has cut management layers, held the dividend at the legal minimum, and concentrated on four priorities: rebuilding the pharma pipeline, containing litigation, reducing debt and improving crop profitability. In 2026 a 7–2 U.S. Supreme Court ruling on federal pre-emption and a proposed USD 7.25 billion class settlement moved the litigation closer to resolution, though the settlement still awaits final court approval. --- **Company's own description.** Bayer describes itself as a global enterprise with core competencies in the life-science fields of health care and nutrition, operating under the mission "Health for all, Hunger for none" (Annual Report 2025; press boilerplate 2026). Bayer AG is a holding company; operations sit in subsidiaries worldwide. In fiscal 2025 the Group had about 88,000 employees, sales of EUR 45.6 billion and R&D expenses of EUR 5.8 billion. **Independent characterisation.** Bayer is best understood as three distinct businesses sharing a balance sheet, a brand and a legal liability. Crop Science (47 percent of FY2025 sales) is an input supplier to farmers. It earns money from proprietary seed and biotech traits, from chemical and biological crop protection, and to a small extent from digital farming subscriptions. Seed and trait revenue carries royalty-like economics: Bayer licenses traits to other seed companies, and two licensing settlements with Corteva lifted results in Q4 2025 and Q1 2026. The business is strongly seasonal, with Northern Hemisphere sales concentrated in the first half and Latin American sales in the second. Pharmaceuticals (39 percent of sales) discovers, develops and sells prescription medicines, concentrated in cardiovascular and renal disease, oncology, women's health and ophthalmology, plus a radiology unit selling contrast agents and injector hardware. Revenue is almost entirely product sales, with some licence income (for example U.S. Xarelto royalties from Johnson & Johnson, and Eylea outside the United States under a collaboration with Regeneron). The division is in the middle of a patent transition: Xarelto and Eylea are declining while Nubeqa and Kerendia are growing quickly. Consumer Health (13 percent of sales) sells non-prescription brands through pharmacies, mass retail and e-commerce. It is a branded consumer-goods model with stable margins and low capital intensity. **Revenue model mix.** Bayer does not disclose a product/service/licensing split. On the evidence of the Annual Report 2025, the large majority of revenue is product sales; licensing income is embedded in Crop Science seed and trait lines and in Pharmaceuticals; subscription revenue (Climate FieldView, radiology software) is immaterial at Group level. An exact percentage split is not publicly disclosed. **Value-chain position.** Bayer is a research-based originator and manufacturer. It owns discovery, development, active-ingredient and finished-product manufacturing, and commercial organisations, and sells through distributors, retailers, wholesalers, hospitals and pharmacies rather than directly to end users in most markets. **Customers and end markets.** Farmers, agricultural retailers and distributors, and seed licensees (Crop Science); wholesalers, hospitals, physicians, pharmacy chains, governments and payers (Pharmaceuticals); pharmacies, supermarkets, drugstores and online retailers (Consumer Health).
4 interactive charts drawn from the Bacillus Pumilus Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Bacillus Pumilus Market By Application Method
Global Bacillus Pumilus Market By Crop Type
Global Bacillus Pumilus Market By Formulation
Global Bacillus Pumilus Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
